Insulin-Like Growth Factor and Epidermal Growth Factor Signaling in Breast Cancer Cell Growth: Focus on Endocrine Resistant Disease

Analytical Cellular Pathology

Volumn 2015, Issue , 2015, Pages

  Voudouri, Kallirroi ^a   Berdiaki, Aikaterini ^a   Tzardi, Maria ^a   Tzanakakis, George N ^a   Nikitovic, Dragana ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; EPIDERMAL GROWTH FACTOR DERIVATIVE; SOMATOMEDIN C;

ANTIPROLIFERATIVE ACTIVITY; BIOAVAILABILITY; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; DISEASE COURSE; ENDOCRINE DISEASE; ENDOCRINE RESISTANT DISEASE; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; BREAST NEOPLASMS; ENDOCRINE SYSTEM; FEMALE; METABOLISM; PATHOLOGY;

BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; EGF FAMILY OF PROTEINS; ENDOCRINE SYSTEM; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; SIGNAL TRANSDUCTION;

EID: 84938099764     PISSN: 22107177     EISSN: 22107185     Source Type: Journal    
DOI: 10.1155/2015/975495     Document Type: Review

References (131)

1. M. W. Beckmann, M. R. Bani, P. A. Fasching, R. Strick, and M. P. Lux, "Risk and risk assessment for breast cancer: molecularand clinical aspects, " Maturitas, vol. 57, no. 1, pp. 56-60, 2007.
2. R. B. Dickson and M. E. Lippman, "Estrogenic regulation ofgrowth and polypeptide growth factor secretion in humanbreast carcinoma, " Endocrine Reviews, vol. 8, no. 1, pp. 29-43, 1987.
3. C. L. Arteaga, L. J. Kitten, E. B. Coronado et al., "Blockadeof the type I somatomedin receptor inhibits growth of humanbreast cancer cells in athymic mice, " The Journal of ClinicalInvestigation, vol. 84, no. 5, pp. 1418-1423, 1989.
4. A. Milani, E. Geuna, G. Mittica et al., "Overcoming endocrineresistance in metastatic breast cancer: current evidence andfuture directions, "World Journal of Clinical Oncology, vol. 5, no. 5, pp. 990-1001, 2014.
5. M. A. Shupnik, "Crosstalk between steroid receptors and thec-Src-receptor tyrosine kinase pathways: implications for cellproliferation, " Oncogene, vol. 23, no. 48, pp. 7979-7989, 2004.
6. J. M. Gee, J. F. Robertson, E. Gutteridge et al., "Epidermalgrowth factor receptor/HER2/insulin-like growth factor receptorsignalling and oestrogen receptor activity in clinical breastcancer, " Endocrine-Related Cancer, vol. 12, supplement 1, pp. S99-S111, 2005.
7. D. J. Riese II and D. F. Stern, "Specificity within the EGFfamily/ErbB receptor family signaling network, " BioEssays, vol. 20, no. 1, pp. 41-48, 1998.
8. N. E. Hynes andD. F. Stern, "The biology of erbB-2/neu/HER-2and its role in cancer, " Biochimica et Biophysica Acta, vol. 1198, no. 2-3, pp. 165-184, 1994.
9. D. Meyer and C. Birchmeier, "Multiple essential functions ofneuregulin in development, " Nature, vol. 378, no. 6555, pp. 386-390, 1995.
10. J. Massagu and A. Pandiella, "Membrane-anchored growthfactors, " Annual Review of Biochemistry, vol. 62, pp. 515-541, 1993.
11. T. Holbro, G. Civenni, andN. E. Hynes, "The ErbB receptors andtheir role in cancer progression, " Experimental Cell Research, vol. 284, no. 1, pp. 99-110, 2003.
12. R. Pinkas-Kramarski, L. Soussan, H. Watermanet al., "DiversificationofNeu differentiation factor and epidermal growth factorsignaling by combinatorial receptor interactions, " The EMBOJournal, vol. 15, no. 10, pp. 2452-2467, 1996.
13. M. A. Olayioye, R. M. Neve, H. A. Lane, and N. E. Hynes, "The ErbB signaling network: receptor heterodimerization indevelopment and cancer, " The EMBO Journal, vol. 19, no. 13, pp. 3159-3167, 2000.
14. Y. Yarden and M. X. Sliwkowski, "Untangling the ErbB signallingnetwork, " Nature Reviews Molecular Cell Biology, vol. 2, no. 2, pp. 127-137, 2001.
15. B. Bucci, I. D'Agnano, C. Botti et al., "EGF-R expression inductal breast cancer: proliferation and prognostic implications, "Anticancer Research, vol. 17, no. 1, pp. 769-774, 1997.
16. S. S. Skandalis, N. Afratis, G. Smirlaki et al., "Cross-talk betweenestradiol receptor and EGFR/IGF-IR signaling pathways inestrogen-responsive breast cancers: focus on the role andimpact of proteoglycans, " Matrix Biology, vol. 35, pp. 182-193, 2014.
17. D. F. Stern, P. A. Heffernan, and R. A. Weinberg, "P185, aproduct of the neu proto-oncogene, is a receptorlike proteinassociated with tyrosine kinase activity, "Molecular and CellularBiology, vol. 6, no. 5, pp. 1729-1740, 1986.
18. X.-F. Dong, Y. Berthois, and P. M. Martin, "Effect of epidermalgrowth factor on the proliferation of human epithelial cancercell lines: correlation with the level of occupied EGF receptor, "Anticancer Research, vol. 11, no. 2, pp. 737-743, 1991.
19. E. R. Levin, "Bidirectional signaling between the estrogenreceptor and the epidermal growth factor receptor, " MolecularEndocrinology, vol. 17, no. 3, pp. 309-317, 2003.
20. X. Fu, C. K. Osborne, and R. Schiff, "Biology and therapeuticpotential of PI3K signaling in ER+/HER2-negative breast cancer, "The Breast, vol. 22, pp. S12-S18, 2013.
21. P.-Y. Chu, T.-K. Li, S.-T. Ding, I.-R. Lai, and T.-L. Shen, "EGFinducedGrb7 recruits and promotes ras activity essential forthe tumorigenicity of Sk-Br3 breast cancer cells, " The Journal ofBiological Chemistry, vol. 285, no. 38, pp. 29279-29285, 2010.
22. J. Mendelsohn and J. Baselga, "The EGF receptor family astargets for cancer therapy, " Oncogene, vol. 19, no. 56, pp. 6550-6565, 2000.
23. E. Gaucci, F. Altieri, C. Turano, and S. Chichiarelli, "TheproteinERp57 contributes to EGF receptor signaling and internalizationin MDA-MB-468 breast cancer cells, " Journal of CellularBiochemistry, vol. 114, no. 11, pp. 2461-2470, 2013.
24. F. Bianchi, A. Magnifico, C. Olgiati et al., "FHIT-proteasomedegradation caused bymitogenic stimulation of the EGF receptorfamily in cancer cells, " Proceedings of the National Academyof Sciences of the United States of America, vol. 103, no. 50, pp. 18981-18986, 2006.
25. J. Filmus, M. N. Pollak, R. Cailleau, and R. N. Buick, "MDA-468, a human breast cancer cell line with a high number ofepidermal growth factor (EGF) receptors, has an amplified EGFreceptor gene and is growth inhibited by EGF, " Biochemical andBiophysical Research Communications, vol. 128, no. 2, pp. 898-905, 1985.
26. S. L. Grant, A. Hammacher, A. M. Douglas et al., "An unexpectedbiochemical and functional interaction between gp130and the EGF receptor family in breast cancer cells, " Oncogene, vol. 21, no. 3, pp. 460-474, 2002.
27. B. D. Adams, D. M. Cowee, and B. A. White, "The roleof miR-206 in the epidermal growth factor (EGF) inducedrepression of estrogen receptor-alpha (EERalpha) signaling anda luminal phenotype in MCF-7 breast cancer cells, " MolecularEndocrinology, vol. 23, no. 8, pp. 1215-1230, 2009.
28. X. Zhang, J. Meng, and Z.-Y. Wang, "A switch role of Src in thebiphasic EGF signaling of ER-negative breast cancer cells, " PLoSONE, vol. 7, no. 8, Article ID e41613, 2012.
29. J.-F. Zheng, L.-C. Sun, H. Liu, Y. Huang, Y. Li, and J. He, "EBP50 exerts tumor suppressor activity by promoting cellapoptosis and retarding extracellular signal-regulated kinaseactivity, " Amino Acids, vol. 38, no. 4, pp. 1261-1268, 2010.
30. W. Yao, D. Feng, W. Bian et al., "EBP50 inhibits EGF-inducedbreast cancer cell proliferation by blocking EGFR phosphorylation, "Amino Acids, vol. 43, no. 5, pp. 2027-2035, 2012.
31. R. Baserga, A. Hongo, M. Rubini, M. Prisco, and B. Valentinis, "The IGF-I receptor in cell growth, transformation and apoptosis, "Biochimica et Biophysica Acta, vol. 1332, no. 3, pp. F105-F126, 1997.
32. D. LeRoith and C. T. Roberts Jr., "The insulin-like growth factorsystem and cancer, " Cancer Letters, vol. 195, no. 2, pp. 127-137, 2003.
33. D. LeRoith, H. Werner, D. Beitner-Johnson, and C. T. RobertsJr., "Molecular and cellular aspects of the insulin-like growthfactor I receptor, " Endocrine Reviews, vol. 16, no. 2, pp. 143-163, 1995.
34. W. H. Daughaday and P. Rotwein, "Insulin-like growth factors Iand II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations, " Endocrine Reviews, vol. 10, no. 1, pp. 68-91, 1989.
35. L. Sepp-Lorenzino, "Structure and function of the insulin-likegrowth factor I receptor, " Breast Cancer Research and Treatment, vol. 47, no. 3, pp. 235-253, 1998.
36. E. Surmacz, "Function of the IGF-I receptor in breast cancer, "Journal of Mammary Gland Biology and Neoplasia, vol. 5, no. 1, pp. 95-105, 2000.
37. E. A. Bohula, M. P. Playford, and V. M. Macaulay, "Targetingthe type 1 insulin-like growth factor receptor as anti-cancertreatment, " Anti-Cancer Drugs, vol. 14, no. 9, pp. 669-682, 2003.
38. A. Ullrich, A. Gray, A. W. Tam et al., "Insulin-like growthfactor I receptor primary structure: comparison with insulinreceptor suggests structural determinants that define functionalspecificity, " The EMBO Journal, vol. 5, no. 10, pp. 2503-2512, 1986.
39. R. Baserga, F. Peruzzi, and K. Reiss, "The IGF-1 receptor incancer biology, " International Journal of Cancer, vol. 107, no. 6, pp. 873-877, 2003.
40. H. Kato, T. N. Faria, B. Stannard, C. T. Roberts Jr., and D. LeRoith, "Essential role of tyrosine residues 1131, 1135, and 1136of the insulin-like growth factor-I (IGF-I) receptor in IGF-Iaction, " Molecular Endocrinology, vol. 8, no. 1, pp. 40-50, 1994.
41. A. Grimberg and P. Cohen, "Role of insulin-like growth factorsand their binding proteins in growth control and carcinogenesis, "Journal of Cellular Physiology, vol. 183, no. 1, pp. 1-9, 2000.
42. S. M. Firth and R. C. Baxter, "Cellular actions of the insulin-likegrowth factor binding proteins, " Endocrine Reviews, vol. 23, no. 6, pp. 824-854, 2002.
43. L. S. Laursen, K. Kjaer-Sorensen, M. H. Andersen, and C. Oxvig, "Regulation of insulin-like growth factor (IGF) bioactivityby sequential proteolytic cleavage of IGF binding protein-4and-5, " Molecular Endocrinology, vol. 21, no. 5, pp. 1246-1257, 2007.
44. J. I. Jones andD. R. Clemmons, "Insulin-like growth factors andtheir binding proteins: biological actions, " Endocrine Reviews, vol. 16, no. 1, pp. 3-34, 1995.
45. C. M. Perks and J. M. P. Holly, "Insulin-like growth factor bindingproteins (IGFBPs) in breast cancer, " Journal of MammaryGland Biology and Neoplasia, vol. 5, no. 1, pp. 75-84, 2000.
46. F. Pekonen, T. Nyman, V. Ilvesmaki, and S. Partanen, "Insulinlikegrowth factor binding proteins in human breast cancertissue, " Cancer Research, vol. 52, no. 19, pp. 5204-5207, 1992.
47. S. E. McGuire, S. G. Hilsenbeck, J. A. Figueroa, J. G. Jackson, and D. Yee, "Detection of insulin-like growth factor bindingproteins (IGFBPs) by ligand blotting in breast cancer tissues, "Cancer Letters, vol. 77, no. 1, pp. 25-32, 1994.
48. M. N. Pollak, E. S. Schernhammer, and S. E. Hankinson, "Insulin-like growth factors and neoplasia, " Nature ReviewsCancer, vol. 4, no. 7, pp. 505-518, 2004.
49. S. Ahmad, N. Singh, and R. I. Glazer, "Role of AKT1 in 17betaestradiol-and insulin-like growth factor I (IGF-I)-dependentproliferation and prevention of apoptosis in MCF-7 breastcarcinoma cells, " Biochemical Pharmacology, vol. 58, no. 3, pp. 425-430, 1999.
50. T. E. Adams, V. C. Epa, T. P. J. Garrett, and C. W. Ward, "Structure and function of the type 1 insulin-like growth factorreceptor, " Cellular and Molecular Life Sciences, vol. 57, no. 7, pp. 1050-1093, 2000.
51. E. C. Martin, M. R. Bratton, Y. Zhu et al., "Insulin-like growthfactor-1 signaling regulates miRNA expression inMCF-7 breastcancer cell line, " PLoSONE, vol. 7, no. 11, Article IDe49067, 2012.
52. J. A. McCubrey, L. S. Steelman, S. L. Abrams et al., "Rolesof the RAF/MEK/ERK and PI3K/PTEN/AKT pathways inmalignant transformation and drug resistance, " Advances inEnzyme Regulation, vol. 46, no. 1, pp. 249-279, 2006.
53. J. Whyte, O. Bergin, A. Bianchi, S. McNally, and F. Martin, "Keysignalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimentalmodels of breast cancer progression and in mammary glanddevelopment, " Breast Cancer Research, vol. 11, no. 5, article 209, 2009.
54. E. K. Jeong, S. Y. Lee, H. M. Jeon, M. K. Ju, C. H. Kim, and H. S. Kang, "Role of extracellular signal-regulated kinase(ERK)1/2 in multicellular resistance to docetaxel in MCF-7cells, " International Journal of Oncology, vol. 37, no. 3, pp. 655-661, 2010.
55. C. L. Mamay, A. M. Mingo-Sion, D. M. Wolf, M. D. Molina, and C. L. VanDen Berg, "An inhibitory function for JNK in theregulation of IGF-I signaling in breast cancer, " Oncogene, vol. 22, no. 4, pp. 602-614, 2003.
56. H. Kato, T. N. Faria, B. Stannard, C. T. Roberts Jr., and D. LeRoith, "Role of tyrosine kinase activity in signal transductionby the insulin-like growth factor-I (IGF-I) receptor: characterizationof kinase-deficient IGF-I receptors and the actionof an IGF-I-mimetic antibody (IR-3), " Journal of BiologicalChemistry, vol. 268, no. 4, pp. 2655-2661, 1993.
57. M. G. Myers Jr., X. J. Sun, andM. F. White, "The IRS-1 signalingsystem, " Trends in Biochemical Sciences, vol. 19, no. 7, pp. 289-293, 1994.
58. M. G. Myers Jr., X. J. Sun, B. Cheatham et al., "IRS-1 is a commonelement in insulin and insulin-like growth factor-I signaling tothe phosphatidylinositol 3-kinase, " Endocrinology, vol. 132, no. 4, pp. 1421-1430, 1993.
59. M. G. Myers Jr., L.-M. Wang, X. J. Sun et al., "Role of IRS-1-GRB-2 complexes in insulin signaling, " Molecular and CellularBiology, vol. 14, no. 6, pp. 3577-3587, 1994.
60. E. Y. Skolnik, C. H. Lee, A. Batzer et al., "The SH2/SH3domain-containing protein GRB2 interacts with tyrosinephosphorylatedIRS1 and Shc: implications for insulin controlof ras signalling, " The EMBO Journal, vol. 12, no. 5, pp. 1929-1936, 1993.
61. R. Baserga, C. Sell, P. Porcu, and M. Rubini, "The role of theIGF-I receptor in the growth and transformation ofmammaliancells, " Cell Proliferation, vol. 27, no. 2, pp. 63-71, 1994.
62. S. Giorgetti, P. G. Pelicci, G. Pelicci, and E. Von Obberghen, "Involvement of Src-homology/collagen (SHC) proteins insignaling through the insulin receptor and the insulin-likegrowth-factor-I-receptor, " European Journal of Biochemistry, vol. 223, no. 1, pp. 195-202, 1994.
63. A. Morrione, B. Valentinis, S. Li, J. Y. T. Ooi, B. Margolis, and R. Baserga, "Grb10: a new substrate of the insulin-like growthfactor I receptor, " Cancer Research, vol. 56, no. 14, pp. 3165-3167, 1996.
64. V. Baron, V. Callja, P. Ferrari, F. Alengrin, and E. VanObberghen, "p125(Fak) focal adhesion kinase is a substratefor the insulin and insulin-like growth factor-I tyrosine kinasereceptors, " The Journal of Biological Chemistry, vol. 273, no. 12, pp. 7162-7168, 1998.
65. C. Arbet-Engels, S. Tartare-Deckert, and W. Eckhart, "CterminalSrc kinase associates with ligand-stimulated insulinlikegrowth factor-I receptor, "The Journal of Biological Chemistry, vol. 274, no. 9, pp. 5422-5428, 1999.
66. S. Zhang, X. Li, R. Burghardt, R. Smith III, and S. H. Safe, "Role of estrogen receptor (ER) alpha in insulin-like growthfactor (IGF)-I-induced responses inMCF-7 breast cancer cells, "Journal of Molecular Endocrinology, vol. 35, no. 3, pp. 433-447, 2005.
67. S. Sarkissyan, M. Sarkissyan, Y. Wu, J. Cardenas, H. P. Koeffler, and J. V. Vadgama, "IGF-1 regulates Cyr61 induced breast cancercell proliferation and invasion, " PLoS ONE, vol. 9, no. 7, ArticleID e103534, 2014.
68. D. Burtrum, Z. Zhu, D. Lu et al., "A fully human monoclonalantibody to the insulin-like growth factor I receptor blocksligand-dependent signaling and inhibits human tumor growthin vivo, " Cancer Research, vol. 63, no. 24, pp. 8912-8921, 2003.
69. S. Yakar, D. LeRoith, and P. Brodt, "The role of the growthhormone/insulin-like growth factor axis in tumor growth andprogression: lessons fromanimal models, " Cytokine and GrowthFactor Reviews, vol. 16, no. 4-5, pp. 407-420, 2005.
70. R. A. Mendoza, E. E. Moody, M. I. Enriquez, S. M. Mejia, and G. Thordarson, "Tumorigenicity of MCF-7 human breast cancercells lacking the p38alpha mitogen-activated protein kinase, "Journal of Endocrinology, vol. 208, no. 1, pp. 11-19, 2011.
71. D. Yee, "Insulin-like growth factor receptor inhibitors: baby orthe bathwater" Journal of theNational Cancer Institute, vol. 104, no. 13, pp. 975-981, 2012.
72. S. Abramovitch and H. Werner, "Functional and physical interactionsbetween BRCA1 and p53 in transcriptional regulation ofthe IGF-IR gene, " Hormone and Metabolic Research, vol. 35, no. 11-12, pp. 758-762, 2003.
73. R. Sarfstein, S. Maor, N. Reizner, S. Abramovitch, and H. Werner, "Transcriptional regulation of the insulin-like growthfactor-I receptor gene in breast cancer, " Molecular and CellularEndocrinology, vol. 252, no. 1-2, pp. 241-246, 2006.
74. Q. Wang, H. Zhang, R. Fishel, and M. I. Greene, "BRCA1 andcell signaling, " Oncogene, vol. 19, no. 53, pp. 6152-6158, 2000.
75. V. Shukla, X. Coumoul, L. Cao et al., "Absence of the full-lengthbreast cancer-associated gene-1 leads to increased expressionof insulin-like growth factor signaling axis members, " CancerResearch, vol. 66, no. 14, pp. 7151-7157, 2006.
76. G. Hudelist, T. Wagner, M. Rosner et al., "Intratumoral IGFIprotein expression is selectively upregulated in breast cancerpatients with BRCA1/2 mutations, " Endocrine-Related Cancer, vol. 14, no. 4, pp. 1053-1062, 2007.
77. N. J. G. Webster, J. L. Resnik, D. B. Reichart, B. Strauss, M. Haas, and B. L. Seely, "Repression of the insulin receptor promoter bythe tumor suppressor gene product p53: a possible mechanismfor receptor overexpression in breast cancer, " Cancer Research, vol. 56, no. 12, pp. 2781-2788, 1996.
78. H. Werner and S. Maor, "The insulin-like growth factor-Ireceptor gene: a downstream target for oncogene and tumorsuppressor action, " Trends in Endocrinology and Metabolism, vol. 17, no. 6, pp. 236-242, 2006.
79. E. M. Fox, T. M. Bernaciak, J. Wen, A. M. Weaver, M. A. Shupnik, and C. M. Silva, "Signal transducer and activator oftranscription 5b, c-Src, and epidermal growth factor receptorsignaling play integral roles in estrogen-stimulated proliferationof estrogen receptor-positive breast cancer cells, " MolecularEndocrinology, vol. 22, no. 8, pp. 1781-1796, 2008.
80. E. M. Fox, J. Andrade, and M. A. Shupnik, "Novel actions ofestrogen to promote proliferation: integration of cytoplasmicand nuclear pathways, " Steroids, vol. 74, no. 7, pp. 622-627, 2009.
81. S. Ali, L. Buluwela, and R. C. Coombes, "Antiestrogens and theirtherapeutic applications in breast cancer and other diseases, "Annual Review of Medicine, vol. 62, pp. 217-232, 2011.
82. C. Barrios, J. F. Forbes, W. Jonat et al., "The sequential use ofendocrine treatment for advanced breast cancer:where arewe"Annals of Oncology, vol. 23, no. 6, pp. 1378-1386, 2012.
83. V.-I. Alexaki, I. Charalampopoulos, M. Kampa et al., "Estrogenexerts neuroprotective effects via membrane estrogen receptorsand rapid Akt/NOS activation, " The FASEB Journal, vol. 18, no. 13, pp. 1594-1596, 2004.
84. B. Dufourny, J. Alblas, H. A. A. M. van Teeffelen et al., "Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase, "The Journal of Biological Chemistry, vol. 272, no. 49, pp. 31163-31171, 1997.
85. T. van Agthoven, J. Veldscholte, M. Smid et al., "Functionalidentification of genes causing estrogen independenceof human breast cancer cells, " Breast Cancer Research andTreatment, vol. 114, no. 1, pp. 23-30, 2009.
86. S. Kahlert, S. Nuedling, M. van Eickels, H. Vetter, R. Meyer, andC. Groh, "Estrogen receptor alpha rapidly activates the IGF-1receptor pathway, " Journal of Biological Chemistry, vol. 275, no. 24, pp. 18447-18453, 2000.
87. R. J. Pietras, "Interactions between estrogen and growth factorreceptors in human breast cancers and the tumor-associatedvasculature, " Breast Journal, vol. 9, no. 5, pp. 361-373, 2003.
88. R. X.-D. Song, Y. Chen, Z. Zhang et al., "Estrogen utilization ofIGF-1-R and EGF-R to signal in breast cancer cells, " The Journalof Steroid Biochemistry and Molecular Biology, vol. 118, no. 4-5, pp. 219-230, 2010.
89. J. M. Hall, J. F. Couse, and K. S. Korach, "The multifacetedmechanisms of estradiol and estrogen receptor signaling, " TheJournal of Biological Chemistry, vol. 276, no. 40, pp. 36869-36872, 2001.
90. R. X.-D. Song, Z. Zhang, Y. Chen, Y. Bao, and R. J. Santen, "Estrogen signaling via a linear pathway involving insulinlikegrowth factor I receptor, matrix metalloproteinases, andepidermal growth factor receptor to activate mitogen-activatedprotein kinase inMCF-7 breast cancer cells, " Endocrinology, vol. 148, no. 8, pp. 4091-4101, 2007.
91. M. H. Faulds, H. Olsen, L. A. Helguero, J.-A. Gustafsson, andL.-A. Haldosn, "Estrogen receptor functional activity changesduring differentiation of mammary epithelial cells, " MolecularEndocrinology, vol. 18, no. 2, pp. 412-421, 2004.
92. A. Migliaccio, M. Di Domenico, G. Castoria et al., "Steroidreceptor regulation of epidermal growth factor signalingthrough Src in breast and prostate cancer cells: steroid antagonistaction, " Cancer Research, vol. 65, no. 22, pp. 10585-10593, 2005.
93. B. D. Gehm, J. M. McAndrews, V. C. Jordan, and J. L. Jameson, "EGF activates highly selective estrogen-responsive reporterplasmids by an ER-independent pathway, " Molecular and CellularEndocrinology, vol. 159, no. 1-2, pp. 53-62, 2000.
94. Y. Hawsawi, R. El-Gendy, C. Twelves, V. Speirs, and J. Beattie, "Insulin-like growth factor-oestradiol crosstalk and mammarygland tumourigenesis, " Biochimica et Biophysica Acta-Reviews on Cancer, vol. 1836, no. 2, pp. 345-353, 2013.
95. S. Nilsson, S. Mkel, E. Treuter et al., "Mechanisms of estrogenaction, " Physiological Reviews, vol. 81, no. 4, pp. 1535-1565, 2001.
96. D. Yee and A. V. Lee, "Crosstalk between the insulin-like growthfactors and estrogens in breast cancer, " Journal of MammaryGland Biology and Neoplasia, vol. 5, no. 1, pp. 107-115, 2000.
97. J. Dupont and D. Le Roith, "Insulin-like growth factor 1 andoestradiol promote cell proliferation of MCF-7 breast cancercells: new insights into their synergistic effects, " Journal ofClinical Pathology: Molecular Pathology, vol. 54, no. 3, pp. 149-154, 2001.
98. R. X. Song, C. J. Barnes, Z. Zhang, Y. Bao, R. Kumar, and R. J. Santen, "The role of Shc and insulin-like growth factor 1receptor inmediating the translocation of estrogen receptor tothe plasma membrane, " Proceedings of the National Academy ofSciences of the United States of America, vol. 101, no. 7, pp. 2076-2081, 2004.
99. Z. Yu, W. Gao, E. Jiang et al., "Interaction between IGF-IR andER Induced by E2 and IGF-I, " PLoS ONE, vol. 8, no. 5, ArticleID e62642, 2013.
100. A.-M. Gaben, M. Sabbah, G. Redeuilh, M. Bedin, and J. Mester, "Ligand-free estrogen receptor activity complements IGF1R toinduce the proliferation of theMCF-7 breast cancer cells, " BMCCancer, vol. 12, article 291, 2012.
101. S. Amin, A. Kumar, L. Nilchi, K. Wright, and M. Kozlowski, "Breast cancer cells proliferation is regulated by tyrosine phosphataseSHP1 through c-junN-terminal kinase and cooperativeinduction of RFX-1 and AP-4 transcription factors, " MolecularCancer Research, vol. 9, no. 8, pp. 1112-1125, 2011.
102. K. N. Stevens, C. M. Vachon, and F. J. Couch, "Geneticsusceptibility to triple-negative breast cancer, " Cancer Research, vol. 73, no. 7, pp. 2025-2030, 2013.
103. N. M. Probst-Hensch, J. H. B. Steiner, P. Schraml et al., "IGFBP2and IGFBP3 protein expressions in human breast cancer:association with hormonal factors and obesity, " Clinical CancerResearch, vol. 16, no. 3, pp. 1025-1032, 2010.
104. A. Bellizzi, M. R. Greco, R. Rubino et al., "The scaffoldingprotein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment inbreast cancer cells, " International Journal of Oncology, vol. 46, no. 3, pp. 1214-1224, 2015.
105. T. M. Brand, M. Iida, E. F. Dunn et al., "Nuclear epidermalgrowth factor receptor is a functional molecular target in triplenegativebreast cancer, " Molecular Cancer Therapeutics, vol. 13, no. 5, pp. 1356-1368, 2014.
106. T. M. Brand, M. Iida, C. Li, and D. L. Wheeler, "The nuclearepidermal growth factor receptor signaling network and its rolein cancer, " DiscoveryMedicine, vol. 12, no. 66, pp. 419-432, 2011.
107. W.-C. Huang, Y.-J. Chen, L.-Y. Li et al., "Nuclear translocation ofepidermal growth factor receptor by Akt-dependent phosphorylationenhances breast cancer-resistant protein expression ingefitinib-resistant cells, "TheJournal of Biological Chemistry, vol. 286, no. 23, pp. 20558-20568, 2011.
108. J. L. Martin, H. C. De Silva, M. Z. Lin, C. D. Scott, and R. C. Baxter, "Inhibition of insulin-like growth factor-bindingprotein-3 signaling through sphingosine kinase-1 sensitizestriple-negative breast cancer cells to egf receptor Blockade, "Molecular CancerTherapeutics, vol. 13, no. 2, pp. 316-328, 2014.
109. P. Chaudhary, S. I. Thamake, P. Shetty, and J. K. Vishwanatha, "Inhibition of triple-negative and Herceptin-resistant breastcancer cell proliferation and migration by Annexin A2 antibodies, "British Journal of Cancer, vol. 111, no. 12, pp. 2328-2341, 2014.
110. N. Afratis, C. Gialeli, D. Nikitovic et al., "Glycosaminoglycans:key players in cancer cell biology and treatment, " The FEBSJournal, vol. 279, no. 7, pp. 1177-1197, 2012.
111. D. Nikitovic, K. Kouvidi, K. Voudouri et al., "The motile breastcancer phenotype roles of proteoglycans/glycosaminoglycans, "BioMed Research International, vol. 2014, Article ID 124321, 13pages, 2014.
112. C. A. Kirkpatrick and S. B. Selleck, "Heparan sulfate proteoglycansat a glance, " Journal of Cell Science, vol. 120, no. 11, pp. 1829-1832, 2007.
113. C. Gialeli, A. D. Theocharis, and N. K. Karamanos, "Rolesof matrix metalloproteinases in cancer progression and theirpharmacological targeting, " The FEBS Journal, vol. 278, no. 1, pp. 16-27, 2011.
114. K. Kessenbrock, V. Plaks, and Z. Werb, "Matrix metalloproteinases:regulators of the tumor microenvironment, " Cell, vol. 141, no. 1, pp. 52-67, 2010.
115. S. Ghosh, R. K. Narla, Y. Zheng et al., "Structure-based design ofpotent inhibitors of EGF-receptor tyrosine kinase as anti-canceragents, " Anti-Cancer Drug Design, vol. 14, no. 5, pp. 403-410, 1999.
116. O. M. Fattah, S. M. Cloutier, C. Kndig et al., "Peptabody-EGF:a novel apoptosis inducer targeting ErbB1 receptor overexpressingcancer cells, " International Journal of Cancer, vol. 119, no. 10, pp. 2455-2463, 2006.
117. Y. Zhan, Y. Zhang, C. Liu et al., "A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor and EGF receptor signaling pathways, " Cancer PreventionResearch, vol. 5, no. 6, pp. 864-873, 2012.
118. J. Anido, P. Matar, J. Albanell et al., "ZD1839, a specificepidermal growth factor receptor (EGFR) tyrosine kinaseinhibitor, induces the formation of inactive EGFR/HER2 andEGFR/HER3 heterodimers and prevents heregulin signalingin HER2-overexpressing breast cancer cells, " Clinical CancerResearch, vol. 9, no. 4, pp. 1274-1283, 2003.
119. M. Segovia-Mendoza, L. Dz, M. E. Gonzlez-Gonzlez et al., "Calcitriol and its analogues enhance the antiproliferativeactivity of gefitinib in breast cancer cells, " The Journal of SteroidBiochemistry and Molecular Biology, vol. 148, pp. 122-131, 2015.
120. R. Roskoski, "The ErbB/HER family of protein-tyrosine kinasesand cancer, " Pharmacological Research, vol. 79, pp. 34-74, 2014.
121. W.-C. Huang, R.-M. Hsu, L.-M. Chi, Y.-L. Leu, Y.-S. Chang, and J.-S. Yu, "Selective downregulation of EGF receptor anddownstream MAPK pathway in human cancer cell lines byactive components partially purified fromthe seeds of Livistonachinensis R. Brown, " Cancer Letters, vol. 248, no. 1, pp. 137-146, 2007.
122. M.-H. Kreuter, R. E. Leake, F. Rinaldi et al., "Inhibition ofintrinsic protein tyrosine kinase activity of EGF-receptor kinasecomplex from human breast cancer cells by the marine spongemetabolite (+)-aeroplysinin-1, " Comparative Biochemistry andPhysiology-Part B: Biochemistry and, vol. 97, no. 1, pp. 151-158, 1990.
123. A. Lluch, P. Eroles, and J.-A. Perez-Fidalgo, "Emerging EGFRantagonists for breast cancer, " Expert Opinion on EmergingDrugs, vol. 19, no. 2, pp. 165-181, 2014.
124. Y.-A. Suh, J.-H. Kim, M. A. Sung et al., "A novel antitumor activityof deguelin targeting the insulin-like growth factor (IGF)receptor pathway via up-regulation of IGF-binding protein-3expression in breast cancer, " Cancer Letters, vol. 332, no. 1, pp. 102-109, 2013.
125. P. Elumalai, R. Arunkumar, C. S. Benson, G. Sharmila, andJ. Arunakaran, "Nimbolide inhibits IGF-I-mediated PI3K/AktandMAPK signalling in human breast cancer cell lines (MCF-7and MDA-MB-231), " Cell Biochemistry & Function, vol. 32, no. 5, pp. 476-484, 2014.
126. G. Badr, O. Garraud, M. Daghestani, M. S. Al-Khalifa, and Y. Richard, "Human breast carcinoma cells are induced toapoptosis by samsum ant venom through an IGF-1-dependantpathway, PI3K/AKT and ERK signaling, " Cellular Immunology, vol. 273, no. 1, pp. 10-16, 2012.
127. J. Chen, R. Hou, X. Zhang, Y. Ye, Y. Wang, and J. Tian, "Calycosinsuppresses breast cancer cell growth via ER-dependentregulation of IGF-1R, p38 MAPK and PI3K/Akt pathways, "PLoS ONE, vol. 9, no. 3, Article ID e91245, 2014.
128. Y. Yang and D. Yee, "Targeting insulin and insulin-like growthfactor signaling in breast cancer, " Journal of Mammary GlandBiology and Neoplasia, vol. 17, no. 3-4, pp. 251-261, 2012.
129. S. A. Byron, K. B. Horwitz, J. K. Richer, C. A. Lange, X. Zhang, and D. Yee, "Insulin receptor substratesmediate distinctbiological responses to insulin-like growth factor receptoractivation in breast cancer cells, " British Journal of Cancer, vol. 95, no. 9, pp. 1220-1228, 2006.
130. A. Gualberto, M. L. Hixon, D. D. Karp et al., "Pre-treatmentlevels of circulating free IGF-1 identify NSCLC patients whoderive clinical benefit from figitumumab, " British Journal ofCancer, vol. 104, no. 1, pp. 68-74, 2011.
131. M. A. Becker, X. Hou, S. C. Harrington et al., "IGFBP ratioconfers resistance to IGF targeting and correlates with increasedinvasion and poor outcome in breast tumors, " Clinical CancerResearch, vol. 18, no. 6, pp. 1808-1817, 2012.